Brief: Seladelpar Granted Revised Breakthrough Therapy Designation For The Treatment Of Primary Biliary Cholangitis
23/10/2023 13:40
Oct 23 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* SELADELPAR GRANTED REVISED BREAKTHROUGH THERAPY
DESIGNATION FOR
THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS INCLUDING PRURITUS
IN PATIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
Source text for Eikon: ID:nGNX1y7RZj
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap